Patents by Inventor Grant E. Gallagher

Grant E. Gallagher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and reagents that specifically detect, distinguish and quantify IFN-LAMBDA2 mRNA from IFN-LAMBDA3 mRNA in humans
    Patent number: 10144974
    Abstract: The present invention provides a method of specifically detecting IFN-?2 mRNA or IFN-?3 mRNA. There is provided a qRT-PCR method specifically detecting, discriminating and quantifying IFN-?2 and IFN-?3 mRNA in a biological sample obtained from a human. There is provided qRT-PCR methods and primers and probes that specifically detect IFN-?2 mRNA but not IFN-?3 mRNA and vice versa in humans in order to detect, quantify and discriminate IFN-?2 mRNA and IFN-?3 mRNA.
    Type: Grant
    Filed: August 31, 2016
    Date of Patent: December 4, 2018
    Assignee: Medical Diagnostic Laboratories, LLC
    Inventors: Grant Gallagher, Grant E. Gallagher, Joyce Eskdale, Rachael Siegel
  • METHODS AND REAGENTS THAT SPECIFICALLY DETECT, DISTINGUISH AND QUANTIFY IFN-LAMBDA2 mRNA FROM IFN-LAMBDA3 mRNA IN HUMANS
    Publication number: 20170009307
    Abstract: The present invention provides a method of specifically detecting IFN-?2 mRNA or IFN-?3 mRNA. There is provided a qRT-PCR method specifically detecting, discriminating and quantifying IFN-?2 and IFN-?3 mRNA in a biological sample obtained from a human. There is provided qRT-PCR methods and primers and probes that specifically detect IFN-?2 mRNA but not IFN-?3 mRNA and vice versa in humans in order to detect, quantify and discriminate IFN-?2 mRNA and IFN-?3 mRNA.
    Type: Application
    Filed: August 31, 2016
    Publication date: January 12, 2017
    Applicant: Medical Diagnostic Laboratories, LLC
    Inventors: Grant Gallagher, Grant E. Gallagher, Joyce Eskdale, Rachael Siegel
  • Methods and reagents that specifically detect, distinguish and quantify IFN-?2 mRNA from IFN-?3 mRNA in humans
    Patent number: 9464321
    Abstract: The present invention provides a method of specifically detecting IFN-?2 mRNA or IFN-?3 mRNA. There is provided a qRT-PCR method specifically detecting, discriminating and quantifying IFN-?2 and IFN-?3 mRNA in a biological sample obtained from a human. There is provided qRT-PCR methods and primers and probes that specifically detect IFN-?2 mRNA but not IFN-?3 mRNA and vice versa in humans in order to detect, quantify and discriminate IFN-?2 mRNA and IFN-?3 mRNA.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: October 11, 2016
    Assignee: Medical Diagnostic Laboratories, LLC
    Inventors: Grant Gallagher, Grant E. Gallagher, Joyce Eskdale, Rachael Siegel
  • METHODS AND REAGENTS THAT SPECIFICALLY DETECT, DISTINGUISH AND QUANTIFY IFN-LAMBDA2 mRNA FROM IFN-LAMBDA3 mRNA IN HUMANS
    Publication number: 20140272994
    Abstract: The present invention provides a method of specifically detecting IFN-?2 mRNA or IFN-?3 mRNA. There is provided a qRT-PCR method specifically detecting, discriminating and quantifying IFN-?2 and IFN-?3 mRNA in a biological sample obtained from a human. There is provided qRT-PCR methods and primers and probes that specifically detect IFN-?2 mRNA but not IFN-?3 mRNA and vice versa in humans in order to detect, quantify and discriminate IFN-?2 mRNA and IFN-?3 mRNA.
    Type: Application
    Filed: March 17, 2014
    Publication date: September 18, 2014
    Applicant: MEDICAL DIAGNOSTIC LABORATORIES, LLC
    Inventors: Grant Gallagher, Grant E. Gallagher, Joyce Eskdale, Rachael Siegel
  • Ex-vivo treatment of T-cells with IFN-?
    Patent number: 8771666
    Abstract: The present invention provides a method of treating Th2-associated diseases and disorders by modulating the expression or secretion of IL-4, IL-5 and IL-13 using interferon lambda (IFN-?). For Th2-associated diseases and disorders, cells of a patient having a Th2-associated disease or disorder are treated ex vivo, with IFN-? and returned to the patient. The present invention also provides a method of ex vivo treatment, in conjunction with co-administration of IFN-?.
    Type: Grant
    Filed: December 13, 2012
    Date of Patent: July 8, 2014
    Assignee: Medical Diagnostics Laboratories, LLC
    Inventors: Grant Gallagher, Joyce Gallagher, Sshekar Srinivas, Jihong Dai, Nicholas Megjugorac, Grant E. Gallagher
  • EX-VIVO TREATMENT OF PERIPHERAL BLOOD LEUKOCYTES WITH IFN-Lambda
    Publication number: 20140050700
    Abstract: The present invention provides a method of treating Th2-associated diseases and disorders by modulating the expression or secretion of IL-4, IL-5 and IL-13 using interferon lambda (IFN-?). For Th2-associated diseases and disorders, cells of a patient having a Th2-associated disease or disorder are treated ex vivo, with IFN-? and returned to the patient.
    Type: Application
    Filed: December 13, 2012
    Publication date: February 20, 2014
    Applicant: Medical Diagnostic Laboratories, LLC
    Inventors: Grant Gallagher, Joyce Gallagher, SShekar Srinivas, Jihong Dai, Nicholas Megjugorac, Grant E. Gallagher
  • Ex-vivo treatment of peripheral blood leukocytes with IFN-?
    Patent number: 8354125
    Abstract: The present invention provides a method of treating Th2-associated diseases and disorders by modulating the expression or secretion of IL-4, IL-5 and IL-13 using interferon lambda (IFN-?). For Th2-associated diseases and disorders, cells of a patient having a Th2-associated disease or disorder are treated ex vivo, with IFN-? and returned to the patient. The present invention also provides a method of ex vivo treatment, in conjunction with co-administration of IFN-?.
    Type: Grant
    Filed: October 27, 2008
    Date of Patent: January 15, 2013
    Inventors: Grant Gallagher, Joyce Eskdale, Shekar Srinivas, Jihong Dai, Nicholas Megjugorac, Grant E. Gallagher
  • Ex-vivo treatment of peripheral plasmacytoid dendritic cells with IFN-lambda
    Patent number: 8282964
    Abstract: The present invention provides an ex vivo method of treating plasmacytoid dendritic cells (pDC) in Th2- or Th17-associated diseases by modulating the cytokine expression or secretion using interferon lambda (IFN-?). For the Th-2 or Th17-associated diseases, pDC cells from a patient having the disease are exposed ex vivo with IFN-? in an effective amount to inhibit cytokine releases. The IFN-? exposed pDC are administered back into the patient. The present invention also provides a method of ex vivo IFN-? treatment of pDC, in conjunction with co-administration of a composition comprising IFN-?.
    Type: Grant
    Filed: November 30, 2009
    Date of Patent: October 9, 2012
    Assignee: Medical Diagnostic Laboratories, LLC
    Inventors: Grant Gallagher, Nicholas Megjugorac, Grant E. Gallagher
  • Ex-vivo treatment of peripheral blood leukocytes with IFN-lambda
    Publication number: 20120058081
    Abstract: The present invention provides a method of treating Th2-associated diseases and disorders by modulating the expression or secretion of IL-4, IL-5 and IL-13 using interferon lambda (IFN-?). For Th2-associated diseases and disorders, cells of a patient having a Th2-associated disease or disorder are treated ex vivo, with IFN-? and returned to the patient.
    Type: Application
    Filed: October 27, 2008
    Publication date: March 8, 2012
    Applicant: Medical Diagnostic Laboratories, LLC
    Inventors: Grant Gallagher, Joyce Eskdale, Shekar Srinivas, Jihong Dai, Nicholas Megjugorac, Grant E. Gallagher
  • Ex-vivo treatment of peripheral blood leukocytes with IFN-lambda
    Publication number: 20110268707
    Abstract: The present invention provides an ex vivo method of treating plasmacytoid dendritic cells (pDC) in Th2- or Th17-associated diseases by modulating the cytokine expression or secretion using interferon lambda (IFN-?). For the Th-2 or Th17-associated diseases, pDC cells from a patient having the disease are exposed ex vivo with IFN-? in an effective amount to inhibit cytokine releases. The IFN-? exposed pDC are administered back into the patient. The present invention also provides a method of ex vivo IFN-? treatment of pDC, in conjunction with co-administration of a composition comprising IFN-?.
    Type: Application
    Filed: November 30, 2009
    Publication date: November 3, 2011
    Applicant: Medical Diagnostic Laboratories, LLC
    Inventors: Grant Gallagher, Nicholas Megjugorac, Grant E. Gallagher